Anixa Biosciences awarded patent for breast cancer vaccine in Mexico

Anixa Biosciences (ANIX) announced that the Mexican Institute of Industrial Property, or IMPI, has issued Patent Number 432748, covering key aspects of the Company’s breast cancer vaccine technology. Anixa’s breast cancer vaccine, developed in collaboration with Cleveland Clinic, represents a novel approach to the prevention and treatment of breast cancer. Anixa’s vaccine is based on immunizing against human alpha-lactalbumin, a protein associated with lactation that is aberrantly expressed in certain types of breast cancer. This “retired” protein vaccine strategy aims to selectively prime the immune system to prevent tumor formation while avoiding harm to normal tissue. The vaccine was invented at Cleveland Clinic, and this patent-along with others related to this technology-has been exclusively licensed to Anixa Biosciences. Positive Phase 1 results showed that the vaccine met all primary endpoints, was safe and well tolerated at the maximum tolerated dose, and elicited protocol-defined immune responses in 74% of participants across all doses tested. Based on these findings, Anixa is moving forward with preparations for a Phase 2 clinical trial.